Features Partner Sites Information LinkXpress
Sign In

Hidden Data Behind Imaging Scans for Cancer May offer New Radiotherapy Strategies

By Medimaging International staff writers
Posted on 30 Jul 2014
Print article
Information hidden in imaging tests could help clinicians more effectively choose the radiation therapy dose needed to kill tumors, suggests a study of more than 300 cancer patients.

The research, to be presented at the 56th annual meeting of the American Association of Physicists in Medicine (AAPM), held during July 28 to August 1, 2014, in Austin, TX, USA, is the largest study to date to use radiomics—extracting statistical data from images and other measurements—to help predict the probable progression of cancer or its response to treatment based on positron emission tomography (PET) imaging scans of patients with non-small-cell lung cancer and head and neck cancer.

“Currently, there is a one-size-fits-all process for selecting radiation therapy doses, which might be too much for some patients and not enough for others,” said Joseph Deasy, PhD, senior author of the study and chair of the department of medical physics at Memorial Sloan-Kettering Cancer Center (New York, NY, USA). “Radiomics will help us know when we can turn down the treatment intensity with confidence, knowing we can still control the disease.”

In the study, researchers performed PET scanning in 163 non-small-cell lung cancer patients and 174 head and neck cancer patients before and after treatment. They extracted a range of information from each tumor, including the intensity value of the PET image, the roughness of the image, and other information, such as how round the tumor was. In PET, the brighter an area is, the higher the intensity, revealing that the tumor is consuming a greater amount of energy from the injected radioactive glucose substitute tracer.

Comparing the data gathered from the before and after scans to how the patient fared—including whether the tumor shrank or how long the patient survived—researchers can create models that will help direct future therapy. In this study, for instance, researchers determined that lung tumors that have a higher uptake of the tracer need to be treated with a higher dose of radiation than is typically prescribed.

“Standard protocol today is to only use PET imaging to define the extent of a tumor to be treated,” said Dr. Deasy. “Based on the information from this study, the data would be extracted from those images and put into models that would tell the physician what dose was required to kill the tumor with a high probability.” He noted that radiomics is a team effort that requires good collaboration between physicians, physicists, and computer scientists.

Related Links:

Memorial Sloan-Kettering Cancer Center

Print article



view channel
Image: New Scenaria SE 64/128-slice Computed Tomography Scanner from Hitachi Medical Systems America (Photo courtesy of Business Wire).

Two new 64/128-Slice CT Scanners Cleared by the FDA

A major diagnostic imaging equipment provider has announced US FDA clearance of two new 64/128-slice Computed Tomography (CT) scanners. The Food and Drug Administration (FDA; Silver Spring, MD, USA)... Read more


view channel

Additional Aggressive Cancers Can Be Found Using Breast MRI Following Mammography Screening

The results of a study published online in the journal Radiology have shown that performing MRI scans, after the discovery of mammography breast cancer findings, sometimes shows larger and more aggressive tumors than those discovered in mammography. Breast Magnetic Resonance Imaging (MRI) is widely used for the screening... Read more


view channel

Fast, Noninvasive Assessment of Chronic Liver Disease Announced as Alternative to Biopsies

A leading ultrasound imaging vendor has presented the clinical benefits of its innovative technology for noninvasive assessment of the severity of liver fibrosis, at the Liver Meeting 2015, in San Francisco (CA, USA). Researchers have published more than 60 items on the reliability and effectiveness of the new technology.... Read more

Nuclear medicine

view channel
Image: Glioblastoma in a PET scanner with (left) and without (right) the YY146 marker (Photo courtesy of Weibo Cai, WISC).

Antibody Cancer Marker Causes Tumors to Light Up

A novel marker attaches to a molecule on highly aggressive brain cancer, resulting in glioblastoma tumor tissue being easily identified in a positron emission tomography (PET) scanner. Developed by... Read more

Industry News

view channel

Long-Term Strategic Managed Medical Equipment Services Partnership Announced

An 18-year strategic collaboration agreement, worth CAD 300 million, between a major medical imaging vendor and the Southwest York Region of Ontario in Canada, has been announced. The partnership is for managed equipment services to help advance medical technology in the Southwest York region, and to expand the accessibility... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.